Focus Rheums| ACR Convergence 2024 Previews

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Jessica Farrell, PharmD, in the Spotlight: Why the ARP Is for Me

  |  Issue: December 2018  |  

Kelly April Tyrrell writes about health, science and health policy. She lives in Madison, Wis.

References

  1. CellCept now listed in medicare drug database for off-label use. Scleroderma Foundation. E-Letter 777. 2018 Aug 31.
  2. Shapiro LS, Toledo-Garcia AE, Farrell JF. Effective treatment of malignant atrophic papulosis (Köhlmeier-Degos disease) with treprostinil—early experience. Orphanet J Rare Dis. 2013 Apr 4;8:52.

Related Articles
    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    In-Office Pharmacist Improves Patient Care

    Would your patients and practice benefit from an on-site pharmacist? Jessica Farrell, PharmD, says a pharmacist enhances patient education and frees up a rheumatologist’s time, enabling them to see more patients and provide better all-around care…

    The 2018 ARHP Merit Awards & ACR Distinguished Fellows

    CHICAGO—At the 2018 ACR/ARHP Annual Meeting in October, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARHP Merit Awards about their individual contributions to advancing rheumatology. You’ll also find interviews…